Background. It has been suggested that reducing exposure to malaria by vector control might impair the development of naturally acquired immunity to malaria. It is also thought that an individual's ability to clear drug-resistant malarial parasites after treatment is enhanced by acquired immunity.
without ITMs by use of a conventional prospective cohort approach, because the protection against transmission afforded by ITMs will confound the comparison. A few studies have reported reductions in various antibody titers in children protected by ITMs [20] [21] [22] . However, these reduced antibody concentrations may simply reflect reduced exposure rather than a child's ability to control or clear infection. It has been suggested that the clearance of Plasmodium falciparum parasites harboring resistance-associated mutations after treatment with an antimalarial drug of reduced efficacy is a robust marker of functional antiparasite immunity [23] . The ability to clear a resistant infection is strongly related to age [23] , correlates with the recognition of certain parasite merozoite surface antigens [24] , and is most likely due to enhancement of the effect of the antimalarial drug by immunity [25, 26] . We hypothesized that if long-term use of ITMs impairs the acquisition of protective immunity, then children with lifetime ITM protection would be less able to clear drug-resistant parasites after treatment than would children who had never had ITM protection.
In 2002, we performed a study in Burkina Faso to investigate the impact of ITMs on the spread of chloroquine (CQ) resistance. The distributions of genetic mutations in the genes pfcrt and pfmdr1 associated with CQ resistance were similar in children with uncomplicated malaria living in villages protected or not protected with insecticide-treated curtains (ITCs). There was no evidence that children living in ITC-protected villages were at increased risk of experiencing CQ treatment failure, compared with children who had never used ITCs [27] . We took advantage of this in vivo study of CQ efficacy to test the hypothesis mentioned above by studying the rate of clearance of P. falciparum parasites harboring the pfcrt-76T mutation in children resident in villages protected by ITCs for 6-8 years and in children resident in neighboring villages that had never used ITMs. There is broad consensus that pfcrt-76T is the main determinant of P. falciparum resistance to CQ. The pfmdr1-86Y mutation has also been associated with CQ resistance in some studies, but any effect is clearly much weaker than that of pfcrt-76T, and it may be the case that pfmdr1-86Y only exerts an effect in the presence of the pfcrt-76 mutation [28] [29] [30] [31] . Thus, in parasites harboring the pfcrt-76T mutation, additional mutations in the pfmdr1 gene probably increase the fitness of parasites resistant to CQ.
SUBJECTS, MATERIALS, AND METHODS
Details of the study within which this work was nested have been published elsewhere [27] . A summary is provided below.
Study site and population. The study took place in Ziniaré and Boussé health districts, Burkina Faso, West Africa. Malaria transmission is intense (entomological inoculation rate [EIR] of 100-300 infective bites/year) and seasonal, with most transmission occurring between July and September [2] . During the malaria transmission season, the prevalence of infection exceeds 90% in children aged 6-59 months, with at least 95% of infections being due to P. falciparum [32] .
Selection of the study villages. The study was performed in 2002 in 18 villages, 9 of which had benefited from the use of ITCs for the preceding 6-8 years and 9 of which had never used ITCs. The populations of all of these villages belong predominantly to the Mossi ethnic group. The 9 ITC villages were selected from among 158 villages that had participated in a trial of the impact of ITCs on all-cause child mortality from 1993 to 1996 [7] and in a subsequent study of the long-term impact of ITCs on child mortality from 1996 to 2001 [17] . From 1996 to 2001, all inhabited houses in the 158 villages were protected by ITCs, which were re-treated annually and replaced as necessary. From 1994 to 2001, surveys carried out between 7 p.m. and 9 p.m. during the peak of malaria transmission to assess the quality of utilization of ITCs indicated that, on average, 50% of door curtains were correctly used in surveyed houses (hanging and covering the door opening) at that time of the evening [17] . The quality of utilization of ITCs was not assessed during the peak of malaria transmission in 2002. The entomological impact of the intervention was monitored until 2000. A substantial and sustained reduction in EIR was observed, resulting in an indoor EIR of !1 infective bite/ person/month by 1998-2000 [33, 34] .
The villages selected for the present study were the largest of the 11 villages in the ITC-protected area with functioning heath centers. In 2002, curtains were re-treated in these 9 villages but, because of funding constraints, not in the other 149 villages. In ITC villages, !1% of the population used insecticidetreated bed nets. The 9 non-ITC villages were located around the ITC-protected area. Criteria for selection of non-ITC villages included the presence of a functioning health care facility, distance from the edge of the ITC-protected area (at least 5 km), ease of access, and a large number of children. The survey on the use of ITMs in 2003 suggested that no resident from these villages had slept in a house protected by an ITC and that !1% used an insecticide-treated bed net.
In vivo study of chloroquine efficacy. We performed an in vivo study of CQ efficacy in children with uncomplicated malaria from August to November 2002 by use of a slightly modified version of the standard World Health Organization (WHO) protocol [35] . Children aged 6-59 months who sought care for an acute febrile illness were screened for inclusion in the study. Inclusion criteria were similar to those described in the WHO protocol [35] , except for 2 modifications concerning the ranges of asexual parasite density and axillary temperature [27] . Children with a fever (temperature range of 37.5ЊC to 40.0ЊC) with no obvious cause other than malaria and with no signs of severe malaria had a fingerprick blood sample (250 mL) obtained for the preparation of a thin and thick blood film, as well as a filter-paper blood spot and measurement of the packed-cell volume. Children who met the inclusion criteria were enrolled in the study after informed consent had been obtained from their parent or caretaker. Eligible children were treated with a standard dose of CQ (25 mg/kg) over 3 days according to national treatment guidelines. All treatments were administered under supervision by a nurse. After completion of treatment, appointments were made for follow-up visits on days 3, 4, 7, and 14 after the start of treatment. Caretakers were advised to bring children back to the health center at any time between these scheduled visits if the condition of the children had worsened. Further thin and thick blood films and filter-paper blood spots were obtained on days 3, 7, and 14 and at any unscheduled visit.
Microscopic diagnosis of malaria. Thin and thick blood films were stained with 3% Giemsa for 45 min. Asexual P. falciparum parasites were counted against 400 white blood cells by 2 independent technicians. In the event of major disagreement (quantitative or qualitative), blood smears were reexamined by a third laboratory technician, and his opinion was taken as the final result. The arithmetic mean of the 2 closest parasite densities was used in the analysis.
Molecular biological analyses. DNA was extracted from filter-paper blood spots by use of the Chelex method [36] . Template DNA was amplified by nested polymerase chain reaction (PCR) for the detection of the pfcrt-K76T and pfmdr1-N86Y alleles, using primers and PCR conditions described elsewhere [28, 37] . PCR products were digested using the ApoI endonuclease-restriction enzyme [28] to detect the substitution of lysine by threonine (K76T) at the pfcrt-76 locus. To detect substitution of aspargine by tyrosine (N86Y) at pfmdr1-86, sequence-specific oligonucleotide probing was performed after nested PCR amplification of the 5 region of the gene [38] . Merozoite surface protein 2 (msp2) gene polymorphisms were investigated by nested PCR on paired samples (before and after treatment) to differentiate recrudescence from reinfection [39] . Details of laboratory procedures have been published elsewhere [27] .
Data processing and statistical analyses. Data were double entered and verified using Epi Info (version 6.0; Centers for Disease Control and Prevention) and were analyzed using STATA (version 8.0; available at: http://www.stata.com). Analyses were restricted to children who carried parasites harboring the pfcrt-76T resistance allele before treatment. Because of PCR failure, several children had missing data on pfcrt-76 (at followup), pfmdr1-86, or P. falciparum msp2 polymorphisms. Multiple imputation (5 imputations) was used to impute values for these missing data points (pfmdr1-86 and msp2 before treatment; pfcrt-76, pfmdr1-86, and msp2 after treatment), assuming that the data were missing at random [40] . Children who carried parasites with the pfcrt-76T mutation after treatment were classified as having failed to clear resistant parasites. Clinical failure was defined in accordance with the standard WHO definition [35] . Clinical and parasitological failures were analyzed as binary outcomes with and without PCR correction for reinfection. Analyses were performed using generalized estimating equations with robust SEs to account for the possibility of between-village variations. Odds ratios (ORs) were adjusted for age, sex, baseline parasite density, ITC use, and carriage of the pfmdr1-86Y allele at enrollment.
Ethics considerations. Authorization to conduct the present study was obtained from the Ministry of Health of Burkina Faso and the ethics committee of the London School of Hygiene and Tropical Medicine. Signed consent was obtained from a parent or caretaker before a child's enrollment in the study. The trial was registered on the National Institute of Health Clinical Trials register (registration no. NCT00169078). respectively ( ). A previous study in the same area had P p .26 also reported similar numbers of clones per infection in ITC and non-ITC villages [41] .
RESULTS

Baseline characteristics of children carrying
Of the 409 children who carried parasites with the pfcrt-76 mutation at baseline, 87 cleared parasitemia (48 in ITC villages and 40 in non-ITC villages) at follow-up, with data on pfcrt-76 missing for 32 samples (7.8%). In ITC villages, 124 (92.5%) of the 134 evaluable children with parasitemia at follow-up carried parasites with the pfcrt-76 mutant allele, whereas the corresponding proportion was 154 (98.7%) of 156 children in non-ITC villages ( ). Data on pfmdr1-86 alleles were P p .01 missing for 24 children (5.9%) at follow-up. Seventy-three (51.0%) of 143 and 91 (58.7%) of 155 evaluable children harbored parasites with the pfmdr1-86Y allele in ITC and non-ITC villages, respectively, at follow-up ( ). Data on msp2 P p .18 polymorphisms either before or after treatment were missing for 12 children (2.9%).
Baseline characteristics of children carrying pfcrt-76 mutant parasites and ability to clear parasites on treatment. Older children were better than younger children at clearing parasites harboring the pfcrt-76T allele (table 2), and girls were better than boys. There was weak evidence ( , test for P p .10 linear trend) that the clearance rate decreased as parasite density increased. Successful clearance did not appear to be associated with the carriage of parasites with the pfmdr1-86Y allele.
Clearance of parasites with the pfcrt-76T allele and ITC use. Children who had lived in villages protected by ITCs since birth were more likely to clear parasites harboring the pfcrt-76T mutation than were children resident in non-ITC villages (34 NOTE. Analyses were performed after multiple imputations for missing data on pfcrt-76, pfmdr1-86, and msp2 and after correction for msp2 and pfcrt-76 at follow-up. Odds ratios (ORs) for the association between insecticide-treated curtain (ITC) use and the clearance of resistant parasites were estimated using a generalized estimating equation model, adjusting for age, sex, baseline parasite density, ITC use, and the presence of pfmdr1-86 alleles at enrollment. The 95% confidence intervals (CIs) were constructed using robust SEs. NOTE. Analyses for the association between insecticide-treated curtain (ITC) use and adequate clinical response in children carrying resistant parasites were performed after multiple imputations for missing data on pfcrt-76, pfmdr1-86, and msp2 and after correction for msp2 and pfcrt-76 at follow-up. Odds ratios (ORs) were estimated using a generalized estimating equation model, adjusting for age, sex, baseline parasite density, ITC use, and the presence of pfmdr1-86Y at enrollment. The 95% confidence intervals (CIs) were constructed using robust SEs.
1.55-3.88];
). 
DISCUSSION
We found no evidence that children aged 6-59 months who had experienced a lifetime of partial protection against malaria as a result of living in ITC villages had impaired immunity to malaria, as measured by their parasitological responses to suboptimal treatment. If ITCs impair the acquisition of immunity to malaria by reducing exposure [11] [12] [13] , we would have expected children in ITC villages to have been less successful in clearing parasites harboring mutations associated with resistance to the treatment given. On the contrary, our data suggest that children protected by ITCs since birth enjoy enhanced functional immunity compared with children living without ITC protection, with the effect being most marked in children under the age of 3 years. It is conceivable that, as exposure increases with age, children living in unprotected villages are able to mount an immune response as effective as that of their counterparts living in protected villages, thus reducing the gap observed at younger age. However, this apparent variation in effect with age could be a chance finding, because we did not find strong evidence of an interaction between age and clearance of drug-resistant parasites. Children of the older age group (36-59 months) represented only 31% of the sample, which may explain our failure to detect evidence of a difference in the clearance of parasites between older children from ITC and non-ITC villages.
Our data on clinical responses showed a pattern similar to that observed for parasitological responses. More children in ITC villages than in non-ITC villages experienced an adequate clinical response. However, given the small number of clinical failures in our study, the observed difference between the groups could have arisen by chance, and our data are compatible with a wide range of scenarios.
How might reduced exposure to malaria, achieved though the use of ITCs, lead to enhanced immunity? It has been sug-gested that chemoprophylaxis, by preventing frequent malarial infections associated with high parasite densities while permitting less frequent infections, might facilitate the development of protective immunity. Some evidence to support this hypothesis was found in a study of chemoprophylaxis in Gambian children; those who had received chemoprophylaxis had stronger cellular immune responses to malarial antigens than did control children [42] . The idea that infrequent, low-density infections might be more effective in inducing protective immunity than frequent high-density infections has also received some support from a trial of intermittent preventive treatment of malaria in infants (IPTi) in Tanzania. In that study, infants who received intermittent preventive treatment with sulfadoxine-pyrimethamine at the time of immunization with diphtheria-tetanus toxoid-pertussis vaccine and polio vaccine had fewer malarial infections during their first year of life than did control children. Surprisingly, protection persisted into their second year of life, long after any drug had been cleared from the circulation, suggesting that reduction of exposure to malaria during the first year of life had had a beneficial effect on the development of long-term immunity [43] . However, this finding has not been confirmed in other IPTi trials. Similarly, protection of infants who have used treated bed nets since birth has been associated with a sustained reduction in the incidence of malaria into late infancy (6-12 months), compared with infants who received bed nets at the age of 6 months [44] . A theoretical model [45] suggests that anti-infection and transmission-blocking vaccines could reduce the virulence of the malarial parasite. The better clearance of parasites in children living in ITC villages might, therefore, be explained by a lower virulence of parasites resulting from reduced malarial infection and transmission associated with long-term use of ITCs. However, our data, in which MOI was similar in the 2 groups of children and in which baseline parasite densities were higher in children from protected villages, do not support this hypothesis. Our findings do not contradict those of previous immunological studies that reported reduced levels of antibodies to various malarial antigens associated with ITM use in the same area [21] or elsewhere [20, 22] , because serological surveys are confounded by recent exposure and because a lower prevalence and lower titers of anti-malarial antibodies is to be expected among children experiencing fewer infectious mosquito bites. Our results are, however, compatible with those of epidemiological studies that found no evidence of an association between use of ITMs and the "delayed" mortality [17] [18] [19] that had been predicted by the immune-deficit hypothesis.
A higher proportion of children in ITC villages than in non-ITC villages had high parasite density at enrollment. A study of severe malaria in children in The Gambia has linked low parasitemia at presentation to anemia and gametocyte carriage, both of which are markers of prolonged P. falciparum infection [46] . Thus, children with higher parasitemia at presentation are more likely to be suffering from an acute febrile incident, as opposed to chronic P. falciparum infection. This is consistent with our data showing that children living in protected villages were better at clearing resistant parasites, suggesting a moreeffective immunity that would help protect against prolonged clinical malaria.
Taken together with the results of previous studies, our results provide strong evidence that the use of ITMs in areas of high transmission intensity does not impair the development of functional immunity to malaria. On the contrary, our data suggest that children protected from malaria by ITMs may acquire functional immunity more rapidly than control children.
